Results 11 to 20 of about 4,782 (272)

Metabolic effects following initiation of single-inhaler triple therapy in COPD: a prospective observational study [PDF]

Molecular Medicine
Background Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, airway inflammation, and oxidative stress. Triple inhaled therapy improves lung function and reduces acute exacerbations, yet its underlying systemic effects ...
Noriane A. Sievi, Felix Schmidt, Diego M. Baur, Kai Fricke, Jonas Herth, Dora Serényi, Maurice Roeder, Nicole Mosca, Silvan Vesenbeckh, Silvia Ulrich, Christian F. Clarenbach, Malcolm Kohler   +11 more
doaj   +2 more sources

Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. [PDF]

ERJ Open Res, 2022
BackgroundThe IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UMEC/VI (62.5/25 μg).
Martin A, Shah D, Ndirangu K, Anley GA, Okorogheye G, Schroeder M, Risebrough N, Ismaila AS.   +7 more
europepmc   +5 more sources

The effectiveness of single inhaler triple therapy in patients with bronchial asthma in real clinical practice [PDF]

Медицинский совет, 2022
Introduction. About 40% of patients with bronchial asthma on dual therapy with inhaled glucocorticosteroids and long-acting β2-agonists do not achieve asthma control.Aim.
V. V. Naumova, E. K. Beltyukov, V. Ch. Abdullaev, E. V. Shevtseva   +3 more
doaj   +3 more sources

The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Life, 2022
There are more single inhaler device triple therapy available for COPD patients now. However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality remains unclear.
Chih-Cheng Lai, Chao-Hsien Chen, Kuang-Hung Chen, Cheng-Yi Wang, Tsan-Ming Huang, Ya-Hui Wang, Hao-Chien Wang   +6 more
doaj   +3 more sources

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma

Advances in Respiratory Medicine, 2023
Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed ...
Serafeim-Chrysovalantis Kotoulas, Ioanna Tsiouprou, Kalliopi Domvri, Polyxeni Ntontsi, Athanasia Pataka, Konstantinos Porpodis   +5 more
doaj   +3 more sources

Single inhaler triple therapy in COPD – all that glitters is not gold

Monaldi Archives for Chest Disease, 2021
Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/
Kartik Deshmukh, Arjun Khanna
doaj   +4 more sources

Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy. [PDF]

ERJ Open Res
BackgroundPatients with COPD on triple therapy often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) analogues may reduce the risk of exacerbation in patients with COPD and type 2 diabetes mellitus (T2DM).
See XY, Xanthavanij N, Lee YC, Ong TE, Wang TH, Ahmed O, Chang YC, Peng CY, Chi KY, Chang Y, Chang KY, Chiang CH.   +11 more
europepmc   +4 more sources

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China

Frontiers in Pharmacology, 2023
Aim: This study sought to compare treatment persistence, adherence, and risk of exacerbation among patients with COPD treated with single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) in the Chinese population.Methods: This was
Ling Lin, Ling Lin, Ling Lin, Cong Liu, Cong Liu, Cong Liu, Wei Cheng, Wei Cheng, Wei Cheng, Qing Song, Qing Song, Qing Song, Yuqin Zeng, Yuqin Zeng, Yuqin Zeng, Xin Li, Dingding Deng, Dan Liu, Yan Chen, Yan Chen, Yan Chen, Shan Cai, Shan Cai, Shan Cai, Ping Chen, Ping Chen, Ping Chen   +26 more
doaj   +3 more sources

Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol [PDF]

Patient Preference and Adherence, 2018
Antonio Molino,1,* Giovanna Calabrese,1,* Mauro Maniscalco2 1Division of Pneumology, Department of Respiratory Diseases, University of Naples Federico II, AORN dei Colli-Monaldi Hospital, Naples, Italy; 2Pulmonary Rehabilitation Division, ICS Maugeri ...
Molino A, Calabrese G, Maniscalco M
doaj   +3 more sources

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

New England Journal of Medicine, 2018
The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA), are uncertain.In this randomized trial involving 10,355 patients with COPD, we ...
David A Lipson, Noushin Brealey, Jean Brooks   +2 more
exaly   +7 more sources